Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. Kawakami H, et al. Among authors: taniguchi h. Oncotarget. 2013 Jan;4(1):9-17. doi: 10.18632/oncotarget.718. Oncotarget. 2013. PMID: 23327903 Free PMC article.
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.
Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M, Nishio K. Yamada Y, et al. Among authors: taniguchi h. Cancer Sci. 2008 Nov;99(11):2193-9. doi: 10.1111/j.1349-7006.2008.00935.x. Epub 2008 Jan 11. Cancer Sci. 2008. PMID: 18957060 Free article. Clinical Trial.
Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer.
Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, Nakajima TE, Shimada Y, Hamaguchi T, Kato K, Taniguchi H, Saito Y, Matsuda T, Moriya Y, Akasu T, Fujita S, Yamamoto S, Nishio K. Yamada Y, et al. Among authors: taniguchi h. Cancer Sci. 2010 Aug;101(8):1886-90. doi: 10.1111/j.1349-7006.2010.01595.x. Epub 2010 Apr 21. Cancer Sci. 2010. PMID: 20491774 Free article.
Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N, Furuta K, Taniguchi H, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y, Yamada Y. Takahashi N, et al. Among authors: taniguchi h. Oncotarget. 2016 Jan 26;7(4):4925-38. doi: 10.18632/oncotarget.6753. Oncotarget. 2016. PMID: 26716644 Free PMC article.
A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302).
Tamura S, Taniguchi H, Nishikawa K, Imamura H, Fujita J, Takeno A, Matsuyama J, Kimura Y, Kawada J, Hirao M, Hirota M, Fujitani K, Kurokawa Y, Sakai D, Kawakami H, Shimokawa T, Satoh T. Tamura S, et al. Among authors: taniguchi h. Int J Clin Oncol. 2020 Dec;25(12):2035-2043. doi: 10.1007/s10147-020-01768-w. Epub 2020 Sep 14. Int J Clin Oncol. 2020. PMID: 32926227 Free PMC article. Clinical Trial.
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N, Yamada Y, Taniguchi H, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Takahashi N, et al. Among authors: taniguchi h. Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13. Arch Med Res. 2014. PMID: 24830936
2,902 results